Latest Asx News

Magnetite Mines Limited has updated its Razorback Iron Ore Project, revealing a 6.6 billion tonne mineral resource and progressing key strategic partnerships and approvals to support green steelmaking ambitions.

Magnetite Mines Limited has announced a renounceable rights issue to raise up to $2.65 million, aiming to fund critical development milestones for its Razorback Iron Ore Project and secure strategic partnerships for DFS funding.

Thunderbird Resources has addressed a recent spike in its share price and volume by releasing previously undisclosed survey results following a trading halt, reaffirming its compliance with ASX rules.

Thunderbird Resources has identified multiple promising geophysical anomalies at its Kookabookra Gold Project in NSW, setting the stage for its maiden drilling campaign in the coming quarter.

Elders Limited faces a regulatory delay from the ACCC on its acquisition of Delta Agribusiness but remains optimistic about the deal's benefits and completion timeline.

Iress Ltd confirms early-stage discussions with Blackstone and Thoma Bravo amid acquisition speculation, following a withdrawn A$10.50 per share offer from Blackstone.

Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.

Greatland Resources has downgraded its FY26 gold production target and significantly increased capital expenditure forecasts for its Telfer Project, prompting a sharp share price reaction and detailed ASX disclosure.

betr Entertainment has increased its offer ratio for acquiring PointsBet shares, signaling a strategic push to secure shareholder approval at the upcoming Selective Buy-Back Meeting.

betr Entertainment has increased its all-scrip takeover offer for PointsBet shares and is seeking shareholder approval for a selective buy-back, reshaping its capital structure and voting dynamics.

PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.

Vection Technologies has reported its first positive underlying EBITDA for FY2025, driven by strong growth in its Defence sector. The company sets ambitious FY2026 revenue targets of $70 million, underpinned by a robust $50 million sales pipeline and cutting-edge AI and spatial computing solutions.